Not real patients

FOR HEALTHCARE PROFESSIONALS

This is a global information resource. It is intended for healthcare professionals outside of the United States of America who are interested in information about ALECENSA. If you are a United States of America healthcare professional please click here.

The European Medicines Agency has approved ALECENSA monotherapy as:1

  • Adjuvant treatment following complete tumour resection for adult patients with ALK+ NSCLC at high risk of recurrence
  • First-line treatment of adult patients with ALK+ advanced NSCLC
  • Treatment of adult patients with ALK+ advanced NSCLC previously treated with crizotinib

The registration status and approved product label of ALECENSA may not be the same in different countries. This website is not country-specific and therefore may contain information which is not applicable to your country. Please refer to your local Summary of Product Characteristics for full details.

This website has been updated according to the latest European Medicines Agency approval in December 2025.

ALK: anaplastic lymphoma kinase; NSCLC: non-small cell lung cancer. 
1. Roche. ALECENSA (alectinib) Summary of Product Characteristics. 2025. Available here (accessed December 2025).
© 2025 F. Hoffmann-La Roche Ltd. M-XX-00021690; Date of preparation: December 2025

Leaving website

You are about to leave the alecensa.global website.

Alecensa
  • About
 ALECENSA
    • NSCLC and biomarker testing
    • Resources centre
  • Resected ALK+ NSCLC
  • Advanced ALK+ NSCLC
  • Download
 SmPC
  • Contact
 Us
Roche logo

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration, or usage in the country of your origin.